Real-world evidence with apixaban for stroke prevention in patients with nonvalvular atrial fibrillation in Germany: a retrospective study (REASSESS)
CI Coleman, M Antz - Internal and emergency medicine, 2017 - Springer
In the Apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation
(ARISTOTLE) trial, apixaban is comparable to a vitamin K antagonist (VKA) in reducing …
(ARISTOTLE) trial, apixaban is comparable to a vitamin K antagonist (VKA) in reducing …
Safety and effectiveness of apixaban in comparison to warfarin in patients with nonvalvular atrial fibrillation: a propensity-matched analysis from Japanese …
S Kohsaka, J Katada, K Saito… - … Medical Research and …, 2018 - Taylor & Francis
Objective: To investigate the risk of bleeding events and stroke/systemic embolism (SE)
among Japanese patients with nonvalvular atrial fibrillation (NVAF), focusing on the initial …
among Japanese patients with nonvalvular atrial fibrillation (NVAF), focusing on the initial …
Comparative effectiveness and safety of apixaban and vitamin K antagonist therapy in patients with nonvalvular atrial fibrillation treated in routine German practice
CI Coleman, WF Peacock, M Antz - Heart, Lung and Circulation, 2018 - Elsevier
Background Scarce data comparing real-world outcomes between apixaban and vitamin K
antagonist (VKA) users with nonvalvular atrial fibrillation (NVAF) are available. We sought to …
antagonist (VKA) users with nonvalvular atrial fibrillation (NVAF) are available. We sought to …
[HTML][HTML] Cost-effectiveness analysis of apixaban against warfarin for stroke prevention in patients with nonvalvular atrial fibrillation in Japan
I Kamae, Y Hashimoto, Y Koretsune, N Tanahashi… - Clinical …, 2015 - Elsevier
Purpose The aim of this study was to evaluate the cost-effectiveness of apixaban compared
with to warfarin, current standard of care, for stroke prevention in patients with nonvalvular …
with to warfarin, current standard of care, for stroke prevention in patients with nonvalvular …
EvaluatioN of ApiXaban in strOke and systemic embolism prevention in patients with non‐valvular atrial fibrillation in clinical practice Setting in France, rationale …
F Picard, E Van Ganse, G Ducrocq… - Clinical …, 2019 - Wiley Online Library
Non‐vitamin K antagonists oral anticoagulants (NOACs) have recently challenged vitamin‐K
antagonists (VKAs) for stroke and systemic embolism prophylaxis in patients with non …
antagonists (VKAs) for stroke and systemic embolism prophylaxis in patients with non …
Apixaban: an update of the evidence for its place in the prevention of stroke in patients with atrial fibrillation
J Seeger, J Wöhrle - Core evidence, 2020 - Taylor & Francis
Oral anticoagulant therapy for stroke prevention in atrial fibrillation patients has been
remarkably changed by the introduction of non-vitamin k oral anticoagulants (NOAC) …
remarkably changed by the introduction of non-vitamin k oral anticoagulants (NOAC) …
Apixaban in Comparison to Warfarin for Stroke Prevention in Nonvalvular Atrial Fibrillation: A Systematic Review and Meta‐Analysis of Observational Studies
MU Siddiqui, D Scalzitti… - Cardiology Research and …, 2019 - Wiley Online Library
Introduction. Atrial fibrillation leads to increased risk of systemic embolism and stroke. To
decrease these adverse events, anticoagulation is routinely prescribed. Nonvitamin K …
decrease these adverse events, anticoagulation is routinely prescribed. Nonvitamin K …
Apixaban 5 and 2.5 mg twice-daily versus warfarin for stroke prevention in nonvalvular atrial fibrillation patients: comparative effectiveness and safety evaluated using …
X Li, A Keshishian, M Hamilton, R Horblyuk, K Gupta… - PLoS …, 2018 - journals.plos.org
Prior real-world studies have shown that apixaban is associated with a reduced risk of
stroke/systemic embolism (stroke/SE) and major bleeding versus warfarin. However, few …
stroke/systemic embolism (stroke/SE) and major bleeding versus warfarin. However, few …
Apixaban for prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation in France: The PAROS cross-sectional study of routine clinical …
B Falissard, F Picard, I Mahe, O Hanon, E Touze… - Archives of …, 2019 - Elsevier
Background Non-vitamin K antagonist oral anticoagulants (NOACs), including apixaban, are
recommended for prevention of stroke and systemic embolism in non-valvular atrial …
recommended for prevention of stroke and systemic embolism in non-valvular atrial …
Real-world use of apixaban for stroke prevention in atrial fibrillation: a systematic review and meta-analysis
Background and Purpose—The use of oral anticoagulant therapy for stroke prevention in
atrial fibrillation has been transformed by the availability of the nonvitamin K antagonist oral …
atrial fibrillation has been transformed by the availability of the nonvitamin K antagonist oral …
相关搜索
- meta analysis stroke prevention
- atrial fibrillation stroke in patients
- atrial fibrillation evaluation of apixaban
- apixaban in comparison stroke prevention
- atrial fibrillation embolism prevention
- atrial fibrillation update of the evidence
- atrial fibrillation effectiveness and safety
- atrial fibrillation practice setting
- effectiveness of apixaban warfarin in patients
- atrial fibrillation meta analysis
- embolism prevention evaluation of apixaban
- fibrillation patients propensity score
- cost effectiveness stroke prevention
- systemic embolism prevention of stroke
- propensity score stroke prevention
- fibrillation patients stroke prevention